Tieshi Zhu: NHANES Study Reveals Significant Mortality Risk With Clopidogrel Monotherapy After PCI
Platelets Journal shared an insightful post on LinkedIn:
“How does clopidogrel monotherapy compare to aspirin after PCI and DAPT?
Building on a recent Korean study that highlighted the efficacy of clopidogrel monotherapy following percutaneous coronary intervention (PCI) and standard dual antiplatelet therapy (DAPT), Zhu et al. (2025) conducted a retrospective analysis of the U.S. NHANES 1999–2018 cohort to compare all-cause mortality between clopidogrel and aspirin monotherapy under similar conditions.
Contrary to previous findings in Asian populations, the authors found that clopidogrel monotherapy was associated with increased risks of all-cause mortality, cardiac mortality, and stroke compared to aspirin monotherapy.”
Read the full article here:
Article: Clopidogrel monotherapy is associated with higher mortality risk compared to aspirin: a retrospective analysis of NHANES 1999–2018
Authors: Tieshi Zhu, Yong He, Yuzhang Bei, Hui Mai, and Le Zhao
Follow the newest developments in clotting science with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia